Quoin Pharmaceuticals, Ltd.
QRX003
Netherton Syndrome
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on QRX003 for Netherton Syndrome is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“FDA conditional approval of the QYLEKI brand name reflects the continued progress we are making toward potential commercialization of the product and complements the regulatory recognition the product has received in the United States, Euro”